Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1 - 20 |
| Number of pages | 20 |
| Journal | Retrovirology |
| Volume | 10 |
| Issue number | 1 (Art. No.: 43) |
| DOIs | |
| Publication status | Published - 2013 |
Cite this
}
A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. / Roche, Michael John; Salimi, Hamid; Duncan, Renee Charlene; Wilkinson, Brendan; Chikere, Kelechi; Moore, Miranda S; Webb, Nicholas; Zappi, Helena; Sterjovski, Jasminka; Flynn, Jacqueline Kaye; Ellett, Anne; Gray, Lachlan Robert; Lee, Benhur; Jubb, Becky; Westby, Mike; Ramsland, Paul Allen; Lewin, Sharon Ruth; Payne, Richard J; Churchill, Melissa; Gorry, Paul R.
In: Retrovirology, Vol. 10, No. 1 (Art. No.: 43), 2013, p. 1 - 20.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations
AU - Roche, Michael John
AU - Salimi, Hamid
AU - Duncan, Renee Charlene
AU - Wilkinson, Brendan
AU - Chikere, Kelechi
AU - Moore, Miranda S
AU - Webb, Nicholas
AU - Zappi, Helena
AU - Sterjovski, Jasminka
AU - Flynn, Jacqueline Kaye
AU - Ellett, Anne
AU - Gray, Lachlan Robert
AU - Lee, Benhur
AU - Jubb, Becky
AU - Westby, Mike
AU - Ramsland, Paul Allen
AU - Lewin, Sharon Ruth
AU - Payne, Richard J
AU - Churchill, Melissa
AU - Gorry, Paul R
PY - 2013
Y1 - 2013
N2 - The CCR5 antagonist maraviroc (MVC) inhibits human immunodeficiency virus type 1 (HIV-1) entry by altering the CCR5 extracellular loops (ECL), such that the gp120 envelope glycoproteins (Env) no longer recognize CCR5. The mechanisms of HIV-1 resistance to MVC, the only CCR5 antagonist licensed for clinical use are poorly understood, with insights into MVC resistance almost exclusively limited to knowledge obtained from in vitro studies or from studies of resistance to other CCR5 antagonists. To more precisely understand mechanisms of resistance to MVC in vivo, we characterized Envs isolated from 2 subjects who experienced virologic failure on MVC.
AB - The CCR5 antagonist maraviroc (MVC) inhibits human immunodeficiency virus type 1 (HIV-1) entry by altering the CCR5 extracellular loops (ECL), such that the gp120 envelope glycoproteins (Env) no longer recognize CCR5. The mechanisms of HIV-1 resistance to MVC, the only CCR5 antagonist licensed for clinical use are poorly understood, with insights into MVC resistance almost exclusively limited to knowledge obtained from in vitro studies or from studies of resistance to other CCR5 antagonists. To more precisely understand mechanisms of resistance to MVC in vivo, we characterized Envs isolated from 2 subjects who experienced virologic failure on MVC.
UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3648390/pdf/1742-4690-10-43.pdf
U2 - 10.1186/1742-4690-10-43
DO - 10.1186/1742-4690-10-43
M3 - Article
VL - 10
SP - 1
EP - 20
JO - Retrovirology
JF - Retrovirology
SN - 1742-4690
IS - 1 (Art. No.: 43)
ER -